GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brightgene Bio-medical Technology Co Ltd (SHSE:688166) » Definitions » Accounts Receivable

Brightgene Bio-medical Technology Co (SHSE:688166) Accounts Receivable : ¥328 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Brightgene Bio-medical Technology Co Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Brightgene Bio-medical Technology Co's accounts receivables for the quarter that ended in Dec. 2024 was ¥328 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Brightgene Bio-medical Technology Co's Days Sales Outstanding for the quarter that ended in Dec. 2024 was 97.83.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Brightgene Bio-medical Technology Co's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was ¥-3.73.


Brightgene Bio-medical Technology Co Accounts Receivable Historical Data

The historical data trend for Brightgene Bio-medical Technology Co's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brightgene Bio-medical Technology Co Accounts Receivable Chart

Brightgene Bio-medical Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only 177.27 373.35 302.82 282.98 327.78

Brightgene Bio-medical Technology Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 282.98 250.81 318.50 369.54 327.78

Brightgene Bio-medical Technology Co Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Brightgene Bio-medical Technology Co Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Brightgene Bio-medical Technology Co's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=327.777/305.726*91
=97.83

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Brightgene Bio-medical Technology Co's accounts receivable are only considered to be worth 75% of book value:

Brightgene Bio-medical Technology Co's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(765.353+0.75 * 327.777+0.5 * 364.615-2726.97
-0-42.728)/422.467
=-3.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Brightgene Bio-medical Technology Co Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Brightgene Bio-medical Technology Co's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Brightgene Bio-medical Technology Co Business Description

Traded in Other Exchanges
N/A
Address
Xinghu Street, Industrial Park, Building C25-C28, Bio-Nano Park, No. 218, Suzhou, CHN, 215123
Brightgene Bio-medical Technology Co Ltd is a pharmaceutical company engaged in research, development and production of new drugs and high-end generic drugs. The company develops macrolides, peptides, polysaccharides, heterocycles, azoles, azines, phenyl ethers, tetracyclines, and production of non-pharmaceutical macrolides, peptides, polysaccharides, heterocycles, azoles, azines, benzene Ethers, tetracyclines.

Brightgene Bio-medical Technology Co Headlines

No Headlines